Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Filing Date: March 9, 2005
Reporting Period: The filing announces the issuance of a press release reporting financial results for the three months and the full year ended December 31, 2004.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) but does not contain the specific financial data within the body of this document. Consequently, the following metrics are not available in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing text does not detail specific material changes or comparative figures versus prior periods. It solely confirms the release of results for the period ended December 31, 2004.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release on March 9, 2005, to report its financial results.
Legal Status of Release: The press release is furnished under Item 2.02 and is explicitly not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It is not subject to the liabilities of that section and shall not be deemed incorporated by reference in any other filing.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 9, 2005) for actual revenue, net loss, and cash position figures, as they are absent from this summary text.
- Verify the company's cash runway and burn rate based on the full year 2004 results found in the attached exhibit.
- Confirm whether the press release contains any updated guidance for 2005 or new clinical trial milestones.
- Note that the press release is not legally "filed" under Section 18, which may impact liability considerations for forward-looking statements contained therein.